

Effects of an oral dose of L-glutamic acid on circulating neurotransmitters: Possible roles of the C₁(Ad) and the A₅(NA) pontomedullary nuclei

Fuad Lechin¹
Bertha van der Dijs¹
Betty Pardey-Maldonado¹
Jairo E Rivera¹
Marcel E Lechin²
Scarlet Baez¹

¹Department of Physiological Sciences, Sections of Neuroendocrinology, Neuropharmacology, and Neurochemistry, Instituto de Medicina Experimental, Faculty of Medicine, Universidad Central de Venezuela, Caracas, Venezuela; ²Department of Internal Medicine, Texas A & M Health Science Center, College of Medicine, Texas, USA

Objective: Investigation of the effects of an oral administration of a small dose of L-glutamic acid on the two peripheral sympathetic branches (neural and adrenal) of the autonomic nervous system.

Research design and methods: Circulating neurotransmitters and cardiovascular parameters were assessed in 28 healthy volunteers before and after the administration of 500 mg of L-glutamic acid or placebo.

Results: The drug triggered a significant and sustained enhancement of the noradrenaline and dopamine circulating levels which were paralleled and positively correlated with the diastolic blood pressure increases. Conversely, both platelet and plasma serotonin showed significant falls throughout the test. Significant positive correlations were registered between noradrenaline, dopamine, and noradrenaline/dopamine ratio versus diastolic blood pressure but not versus systolic blood pressure or heart rate.

Conclusion: The above results allowed us to postulate that the drug provoked a significant enhancement of peripheral neural sympathetic activity and the reduction of adrenal sympathetic and parasympathetic drives. Both sympathetic branches are positively correlated with the A₅ noradrenergic and the C₁ adrenergic pontomedullary nuclei, which interchange inhibitory axons that act at post-synaptic α_2 inhibitory autoreceptors. In addition, we discussed the mechanisms able to explain why the drug acted preferentially at the A₅ noradrenergic rather than the C₁ adrenergic nuclei.

Keywords: glutamic acid, catecholamines, noradrenaline, serotonin, sympathetic activity

Introduction

The C₁ adrenergic (Ad) and the A₅ noradrenergic (NA) pontomedullary nuclei are the master controllers of the peripheral adrenal and neural branches of the sympathetic nervous system, respectively. Both central nervous system nuclei interchange inhibitory axons that are crowded by α_2 postsynaptic receptors. However, the C₁(Ad) but not the A₅(NA) neurons are also crowded by imidazole inhibitory receptors. Other evidence showed that adrenal glands secrete adrenaline (80%) and noradrenaline plus dopamine (20%) whereas sympathetic nerves release noradrenaline (80%) plus dopamine (20%), approximately. Both peripheral sympathetic branches may act in association or dissociation in accordance with physiological or pathophysiological demands.¹⁻⁵

Although it was established that the C₁(Ad) nuclei receives excitatory glutamatergic (GLUT) axons which act at N-methyl-D-aspartic acid (NMDA) receptors located at these levels, no definite conclusion has been reached on the direct physiological effect triggered by GLUT axons at the A₅(NA) nucleus. Both excitatory and inhibitory blood pressure responses to this interaction have been reported.⁶⁻¹³

Correspondence: Fuad Lechin
Apartado 80.983, Caracas 1080-A,
Venezuela
Email flechin@telcel.net.ve

In addition to the above, other indirect, polysynaptic mechanisms are able to influence the A_5 (NA) and C_1 (Ad) interaction. For instance, the C_1 (Ad) interchange excitatory axons with the dorsal raphe serotonergic [DR(5HT)]¹⁴ and the A_6 (NA) (locus coeruleus)¹⁵ nuclei whereas the A_5 (NA) nucleus interchanges inhibitory axons with the A_6 (NA) neurons and cooperates with the median raphe serotonergic (MR-5HT) and in addition, the A_5 (NA) receives inhibitory axons from the DR(5-HT) neurons.^{16,17} According to all the above, the C_1 (Ad) vs A_5 (NA) direct antagonism is modulated by a complex NA + 5HT pontomedullary circuitry addressed to avoid the black vs white peripheral autonomic nervous system (ANS) responses. In addition to all the above, the peripheral ANS sends signals (neural and/or neurotransmitters) to the C_1 (Ad) + A_5 (NA) binomial in order to attenuate the peripheral ANS unbalances triggered by both physiological and pathophysiological circumstances.⁴ For instance: electrical excitation of the A_5 (NA) nucleus provokes blood pressure reduction. This effect is mediated by the cholinergic (ACh) nucleus tractus solitarius which receives excitatory axons from the former.¹⁸ Hence we decided to investigate the effects of an oral dose of L-glutamic acid on circulating neurotransmitters in order to find more information addressed to shed more light on the role played by the A_5 (NA) neurons on the peripheral sympathetic nervous system.

Methods

Experimental design

Levels of plasma noradrenaline, adrenaline, dopamine, free serotonin (f5-HT), and platelet serotonin (p5-HT) were measured before (0 minutes) and after (60, 90, 120 minutes) the oral administration of 500 mg of L-glutamic acid in 28 healthy volunteers. Similar measurements were performed two weeks before, in the same volunteers after oral administration of placebo. The group of volunteers comprised 12 men and 16 women, whose ages ranged from 19 to 60 years (mean \pm SE = 38.9 \pm 7.4). Informed consent was obtained in writing from all volunteers, and the procedure was approved by the ethical committee of FUNDAIME. All volunteers were within 10% of ideal body weight, none had any physical or psychiatric illness. Exclusion criteria included pregnancy, lactation, smoking, and alcohol abuse. Volunteers were recumbent during all procedures. A physician in constant attendance noted any symptoms reported by the subjects and monitored heart rate and blood pressure. The study was conducted in accordance with the guidelines in the Declaration of Helsinki. Written informed consent was obtained after the purpose, nature and potential risks had been explained

to the subjects. The experimental protocol was approved by the ethical committee of FUNDAIME.

Analytical methods

Noradrenaline, adrenaline, dopamine, plasma-free serotonin, and platelet serotonin were measured throughout the 120-minute testing period. For all parameters, the samples were assayed in duplicate and all determinations were made simultaneously. We used reverse-phase, ion-pair high-performance liquid chromatography with electrochemical detection for the detection of monoamines. Optimization of chromatographic conditions and attainment of adequate quantification parameters allowed us to maximize sensitivity and reproducibility.

All tests were performed on recumbent subjects after 14 hours of fasting. A heparinized venous catheter was inserted into a forearm vein at least 30 minutes before beginning the tests. Blood samples were collected at 0, 30, 60, 90 and 120 minutes. Each subject took an oral dose of 500 mg L-glutamic acid (one tablet) or similar tablet containing placebo. Blood for catecholamines and serotonin assays was transferred to plastic tubes, each containing 20 mg of EDTA plus 10 mg of sodium bisulphite/mL of solution. The tubes were carefully inverted and placed on ice. The blood was promptly centrifuged at 600 rpm for 15 min at 4°C in order to obtain platelet-rich plasma. Two milliliters of platelet-rich plasma, obtained for determination of platelet serotonin (p5-HT), were taken and stored at -70°C until assayed. The remaining blood was again centrifuged at 7,000 rpm. The supernatant, platelet-poor plasma, was divided into two portions for determination of catecholamines and free serotonin (f5-HT), after which the portions were stored at -70°C until assayed.

Reagents and standards

Noradrenaline, adrenaline, dopamine, serotonin creatinine sulphate, dihydroxybenzylamine, sodium octyl sulphate, dibutylamine, acid-washed aluminium oxide, Na_2HPO_4 , citric acid and EDTA were purchased from Sigma-Aldrich (St. Louis, MO, USA). Microfilters were purchased from Whatman Inc. (Florham Park, NY, USA) through Merck South Africa (Caracas, Venezuela). Acetonitrile and 2-propanol were obtained from Merck South Africa. Glass-distilled water was de-ionized and filtered through a Milli-Q reagent grade water system (Millipore, Bedford, MA, USA). Solvents were filtered through a 0.2 μ m Millipore filter and were vacuum de-aerated. Standard solutions (1 mmol/L) were prepared in 0.1 mol/L perchloric acid and diluted to the desired concentration.

Equipment

Liquid chromatography was performed using Waters 515 HPLC pump (Waters Corporation, Milford, MA, USA) equipped with a Rheodyne valve injector 7125i, which was fitted with a 50 μ L sample loop (Rheodyne; Berodine, Berkeley, CA, USA). A 15 cm \times 4.6 mm inner diameter Discovery C18 column packed with octadecylsilane 5 μ m particles was preceded by a column prefilter of 2 μ m porosity, both from Supelco/Sigma-Aldrich. The detection system was a Waters 460 Electrochemical Detector (Waters Corporation). The potential of the working electrode (glass carbon) was set at +0.61 V versus the Ag-AgCl reference electrode for the detection of catecholamines and 0.70 V versus the Ag-AgCl for the detection of indolamines. The chromatograms were registered and quantified with the Empower software from Waters Corporation. The results were corrected for the volume of EDTA added.

Analytical assays

Plasma catecholamines

The assay was performed by extraction of the catecholamines onto 20 mg of alumina followed by their elution with 200 μ L of 1.0 mol/L HClO₄ using regenerated cellulose microfilters 0.2 μ m pore size (Whatman Inc.). We calibrated the instrument with standard plasma: after incubation with acid-washed aluminum oxide, a plasma pool of free catecholamines was processed similarly to plasma samples, but 20 μ L of a standard solution of noradrenaline, adrenaline and dopamine (50, 25 and 25 ng/mL, respectively) were added to the plasma pool. Both the standard plasma and the sample plasma were supplemented with 20 μ L of internal standard (100 ng/mL of dihydroxybenzylamine). The mobile phase was KH₂PO₄ 6.8045 g/L, EDTA 0.100 g/L and di-N-butylamine 100 μ L/L. Sodium octyl sulphate was added as ion-pair agent in a concentration of 0.6125 g/L with the pH adjusted to 5.6. The flow rate was 0.400 mL/min. The sensitivity of this method for noradrenaline, adrenaline and dopamine was 6.4, 5.8, and 2.0 pg/mL, respectively. The intra-assay coefficients of variation were 2.8%, 4.0%, and 4.0%, respectively. The inter-assay coefficients of variation were 6.7%, 4.5%, and 4.3%, respectively.

Plasma indolamines

After sonication of platelet-rich plasma to disrupt the platelets (Ultrasonic Liquid Processor, model 385; Heat Systems Ultrasonics Inc., Farmingdale, NY, USA), both platelet-rich and platelet-poor plasma were processed in the same way: 200 μ L of 3.4 mol/L perchloric acid and 50 μ L of

5-hydroxy-tryptophan solution (114.5 μ g/mL) as internal standard, were added to 1 mL of plasma vortexed and centrifuged at 10,000 rpm for 15 minutes at 4°C. The supernatant was filtered through a 0.22 μ m membrane (Millipore) and 10 μ L was injected into the column. Calibration runs were generated by spiking blank platelet-poor plasma with 50 μ L of a solution containing 5-HT (10 μ g/mL) and 50 μ L of 5-hydroxy-tryptophan (114.5 μ g/mL). This standard plasma was processed in the same manner as the samples. The mobile phase was citric acid 3.8424 g/L, sodium acetate 4.1015 g/L, EDTA 0.100 g/L, di-N-butylamine 100 μ L/L and 30 mL/L of 2-propanol. Sodium octyl sulphate was added as ion-pair agent in a concentration of 4.25 mg/L with a pH of 5.0. The flow rate was 0.610 mL/min. The sensitivity of the method for serotonin was 0.1 ng/mL. The intra-assay coefficients of variation for p5-HT and f5-HT were 6.2% and 8.7%, respectively.

Statistical methods

Results are presented as the mean \pm SEM. Multivariate analysis of variance (ANOVA) with repeated measurements, paired t test, and correlation coefficients (exploratory factor analysis) were used. Dbase Stats™ (Ashton Tate, Torrance, CA, USA) and StatView SE + Graphics (SAS Institute, Cary, NC, USA) were used for statistical analyses.

Results

Noradrenaline was significantly raised at all periods following L-glutamic acid administration. Maximal increases in plasma noradrenaline occurred at the 120 minute period. Sustained, progressive and significant decreases of adrenaline values were observed throughout the test. Dopamine plasma levels increased significantly. The NA/Ad ratio showed greatly significant and progressive increases as of the first 60-minute period (Figure 1). We noted significant positive correlations between noradrenaline and dopamine values between the 60- and 120-minute periods.

Moderated but significant decreases of free serotonin in the plasma and platelet serotonin were found throughout the 120 minutes of the experimental trial, the f-5HT/p-5HT ratio did show significant and progressive reduction from the 60 min period until the end of the trial (Figure 2).

Neither heart rate nor systolic blood pressure showed significant changes throughout the experimental trial. Diastolic blood pressure showed slight but significant increase from the 60-minute period until the 120-minute period (Figure 3).




Figure 1 Oral L-glutamic acid administration (500 mg) but not placebo enhanced noradrenaline and dopamine plasma levels in 28 normal healthy volunteers. Adrenaline values showed significant and progressive decreases.
Notes: * $P < 0.02$; ** $P < 0.01$; *** $P < 0.005$. (L-Glutamic acid versus placebo).




Figure 2 Oral L-glutamic acid administration (500 mg) but not placebo decreased plasma serotonin (f5-HT), platelet serotonin (p5-HT) and the f5-HT/p5-HT ratio in 28 normal healthy volunteers.
Notes: * $P < 0.02$; ** $P < 0.01$; *** $P < 0.005$. (L-Glutamic acid versus placebo).




Figure 3 Oral L-glutamic acid administration (500 mg) but not placebo enhanced diastolic blood pressure in 28 normal healthy volunteers. Neither systolic blood pressure nor heart rate showed changes.
Notes: * $P < 0.02$; ** $P < 0.01$; *** $P < 0.005$. (L-Glutamic acid versus placebo).

Correlations

Significant positive correlations were found between NA vs NA/Ad ratio ($r = 0.83$; $P < 0.005$) and NA vs DA ($r = 0.61$; $P < 0.01$). The former tended to rise from the first to the last (post L-glutamic acid) period. The NA vs DA correlation showed progressive rises throughout the trial. These findings indicate that both NA and DA arose from the same source (sympathetic nerves) rather than adrenal glands. The parallelism registered between these two parameters is consistent with the NA vs DA positive correlation.

Noradrenaline vs diastolic blood pressure correlation values at post drug periods were: $r = 0.66$, 0.78 , and 0.85 ($P < 0.01$; $P < 0.01$; and $P < 0.005$, respectively). Dopamine vs diastolic blood pressure-positive correlations were also significant at 90-minute and 120-minute periods; r values were: 0.63 and 0.78 , respectively ($P < 0.01$).

Significant positive correlations were found between DA vs diastolic blood pressure, at the 90-minute and 120-minute periods; r values: 0.68 and 0.72 ($P < 0.02$ in both cases).

Significant and progressive negative correlations were found between the NA/Ad ratio vs the f5-HT/p5-HT ratio from the 60-minute period until the trial's end; r : -0.65 , -0.72 , and -0.84 ($P < 0.02$; $P < 0.02$; and $P < 0.01$, respectively).

Significant positive correlations were found between NA/Ad vs diastolic blood pressure values at 90-minute and 120-minute periods; *r* values: 0.81 and 0.96, respectively ($P < 0.005$ in both cases).

Discussion

The results obtained from the present study demonstrated that a small oral dose of glutamate was enough to enhance neural sympathetic activity, as demonstrated by the increase of the NA/Ad plasma ratio plus the DBP rises.^{3,4,16,17} In addition, the minimization of the plasma-free serotonin (f5-HT) (in the absence of platelet aggregation) should be explained by the decrease of acetylcholine plasma levels (parasympathetic hypoactivity), which competes with serotonin for platelet uptake.^{19,20} Furthermore, the significant fall of total blood serotonin [platelet serotonin (p5-HT + f5-HT)] registered in this study should be attributed to the attenuation of the intestinal (enterochromaffin cells) secretion which depends on the excitatory parasympathetic plus the inhibitory sympathetic nerves.^{21–23} Taking into account that GLUT axons excite both the C₁(Ad) medullary nuclei and the A₅(NA) neurons, which are crowded by NMDA receptors,^{24,25} the facts sprouted from this study are consistent with the postulation that the drug increased A₅(NA) rather than the former nuclei.

The A₆(NA) and the C₁(Ad) nuclei present physiological differences when compared to the A₅(NA) nucleus. For instance, the two former should receive excitatory drives to fire (clonic excitation),²⁶ whereas the A₅(NA) neurons shows tonic, continuous firing activity.¹⁰ This latter displays minimal firing at the REM sleep period, at which level, very low diastolic blood pressure is registered.^{27,28} In addition the two former nuclei [A₆(NA) and C₁(Ad)] but not the A₅(NA) are excited by ACh-axons which arise from the medullary vagal complex and the pedunculopontine nucleus (PPN).²⁹ However, not only the A₆(NA) and the C₁(Ad) but also the A₅(NA) nucleus send modulatory axons to the medullary acetylcholinergic complex nucleus tractus solitarius, nucleus ambiguus, nucleus reticularis giganteo cellularis and others.^{30,31}

Findings obtained from the present study showed that a small oral dose of glutamate was able to enhance neural sympathetic but not adrenal sympathetic activity. These findings indicated that the A₅(NA) but neither the C₁(Ad) nor the A₆(NA) was excited by the drug. These results fit well with the above mentioned findings referred to the tonic but not clonic activity display by the former.^{32–36}

In addition to all the above, other mechanisms should be commented. For instance, both the A₅(NA) and the C₁(Ad)

nuclei send inhibitory and excitatory axons, respectively, to the medullary vagal complex which are responsible for the blood pressure and the heart rate (HR) modulation thus, results obtained from this research fit well with the A₅(NA) but not the C₁(Ad) excitation. Additionally, this postulation is in accordance with other studies which showed that the C₁(Ad) but not the A₅(NA) are crowded by excitatory ACh receptors² which would interfere with both the DBP and plasma NA rises, registered in this study.

Some other experimental studies reported that direct administration of glutamic acid into the A₅(NA) nucleus provoked blood pressure reduction instead of rise.¹⁸ With respect to this, we believe that this should be attributed to the enhancement of the inhibition of the C₁(Ad) plus the excitation of the vagal medullary nuclei (nucleus tractus solitarius, dorsal vagal complex). Both adrenergic and parasympathetic nuclei receive inhibitory and excitatory axons from the A₅(NA) nucleus. Furthermore, considering that the C₁(Ad) rostral ventrolateral medullary nuclei is innervated by excitatory glutamatergic axons which act at NMDA receptors, located at this level, the minimization instead of the enhancement of both plasma Ad and cardiovascular parameters (systolic blood pressure and HR) registered in this study, discards the above possibility.

Glutamate axons are also able to excite NA neurons located at the A₆(NA) (locus coeruleus) neurons which are crowded by NMDA receptors, however, these NA neurons exerts modulatory but not direct effects at the peripheral sympathetic activity. A₆(NA) axons are able to inhibit and excite A₅(NA) and dorsal vagal complex, respectively, which attenuate excessive blood pressure rises and falls, respectively.³⁷ According to all the above, it is possible to postulate that the NA/Ad plasma ratio plus the diastolic blood pressure rises triggered by a small oral dose of L-glutamic acid administered to normal subjects excited neural but not adrenal sympathetic activity.

Additional findings which show that the A₆(NA) and the C₁(Ad) but not the A₅(NA) receive ACh excitatory and GABA inhibitory axons^{38–46} offer more data which helps to understand the discriminative effects exerted by the oral glutamate challenge.

Considering that GLUT axons exert powerful excitatory effects on the MR serotonergic (5-HT) but not at the DR(5-HT) neurons,^{14,17,47} we should include some additional comments to this respect. The DR(5-HT) interchanges excitatory axons with the C₁(Ad) nuclei.^{14,40} Conversely, the A₅(NA) receives inhibitory axons from the DR(5-HT) nucleus.⁴⁸ In addition, the MR(5-HT) neurons, which display clear antagonism

with the DR(5-HT) nucleus, cooperate with the A₅(NA) drives at the nucleus centralis amygdala (CEA) and the bed nucleus stria terminalis levels.^{2,3,49} This additional central nervous system circuitry, which includes hypothalamic circuitry, is responsible for the peripheral neural sympathetic activity, whose hyperactivation is able to modulate the C₁(Ad) + DR(5-HT) axis, responsible for the peripheral adrenal sympathetic branch, as demonstrated in the present experimental study.

The results obtained from this study, helps to understand the controversial findings reported by Neil and colleagues,¹⁸ which showed that the direct glutamate injection at the A₅(NA) nucleus was able to annul rather than excite neural sympathetic activity. This A₅(NA) neural sympathetic activation reported in this study is able to antagonize the DR(5-HT) plus C₁(Ad) axis responsible for the peripheral adrenal sympathetic branch. The fact that GLUT axons excite both the A₅(NA) plus the MR(5-HT) neurons but not the DR(5-HT) nucleus (which is crowded by inhibitory GABA neurons), fits well with all the above.¹⁷

Summarizing, the oral administration of a small dose of glutamate (500 mg) was able to enhance A₅(NA) neurons which display tonic rather than clonic firing activity but not the C₁(Ad) plus A₆(NA) neurons that display clonic firing activity. These findings fit well with others showing that the two latter but not the former receive ACh excitatory and GABA inhibitory axons. Finally, considering that A₅(NA) neurons do not cease to fire might (tonic activity) explain its accessibility to the GLUT agonist which is not counteracted by inhibitory GABA drives.

Disclosures

The authors report no conflicts of interest in this work.

References

1. Young JB, Rosa RM, Landsberg L. Dissociation of sympathetic nervous system and adrenal medullary responses. *Am J Physiol*. 1984;247(1 Pt 1):E35–E40.
2. Lechin F, van der Dijs B. Central nervous system circuitries underlying two types of peripheral autonomic nervous system disorders. *The Open Neurosci J*. 2008;2:41–50.
3. Lechin F, van der Dijs B. Central nervous system plus autonomic nervous system disorders responsible for the gastrointestinal and pancreatobiliary diseases. Review *Dig Dis Sci*. 2009;54:458–470.
4. Lechin F, van der Dijs B. Crosstalk between the autonomic nervous system and the central nervous system: Mechanistic and therapeutic considerations for neuronal, immune, vascular, and somatic based diseases. In: Maiese K, editor *Neurovascular Medicine: Pursuing Cellular Longevity for Healthy Aging*. New York: Oxford University Press, 2009. p. 101–152.
5. Bazil MK, Gordon FJ. Sympathoexcitation from the rostral ventrolateral medulla is mediated by spinal NMDA receptors. *Brain Res Bull*. 1993;31(3–4):273–278.

6. Willette RN, Barcas PP, Krieger AJ, et al. Vasopressor and depressor areas in the rat medulla. Identification by microinjection of L-glutamate. *Neuropharmacology*. 1983;22(9):1071–1079.
7. Byrum CE, Guyenet PG. Afferent and efferent connections of the A5 noradrenergic cell group in the rat. *J Comp Neurol*. 1987;261(4):529–542.
8. Drye RG, Baisden RH, Whittington DL, et al. The effects of stimulation of the A5 region on blood pressure and heart rate in rabbits. *Brain Res Bull*. 1990;24(1):33–39.
9. Andrade R, Aghajanian GK. Single cell activity in the noradrenergic A-5 region: responses to drugs and peripheral manipulations of blood pressure. *Brain Res*. 1982;242(1):125–135.
10. Maiorov DN, Wilton ER, Badoer E, et al. Sympathetic response to stimulation of the pontine A5 region in conscious rabbits. *Brain Res*. 1999;815(2):227–236.
11. Stanek KA, Neil JJ, Sawyer WB, et al. Changes in regional blood flow and cardiac output after L-glutamate stimulation of A5 cell group. *Am J Physiol*. 1984;246(1 Pt 2):H44–H51.
12. Dampney RA, Moon EA. Role of ventrolateral medulla in vasomotor response to cerebral ischemia. *Am J Physiol*. 1980;239(3):H349–H358.
13. Guyenet PG. Baroreceptor-mediated inhibition of A5 noradrenergic neurons. *Brain Res*. 1984;303(1):31–40.
14. Peyron C, Luppi PH, Fort P, et al. Lower brainstem catecholamine afferents to the rat dorsal raphe nucleus. *J Comp Neurol*. 1996;364(3):402–413.
15. Astier B, Van Bockstaele EJ, Aston-Jones G, et al. Anatomical evidence for multiple pathways leading from the rostral ventrolateral medulla (nucleus paragigantocellularis) to the locus coeruleus in rat. *Neurosci Lett*. 1990;118(2):141–146.
16. Lechin F, van der Dijs B. Central nervous system circuitry and peripheral neural sympathetic activity responsible for essential hypertension. Review. *Curr Neurovasc Res*. 2006;3(4):307–325.
17. Lechin F, van der Dijs B, Hernandez-Adrian G. Dorsal Raphe (DR) vs Median Raphe (MR) serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: Relevance for neuropharmacological therapy. Review. *Prog Neuro-Psychopharmacol Biol Psychiatry*. 2006;30(4):565–585.
18. Neil JJ, Loewy AD. Decreases in blood pressure in response to L-glutamate microinjections into the A5 catecholamine cell group. *Brain Res*. 1982;241(2):271–278.
19. Larsson K, Carlens P, Bevegard S, et al. Sympathoadrenal responses to bronchoconstriction in asthma: an invasive and kinetic study of plasma catecholamines. *Clin Sci*. 1995;88:439–446.
20. Rausch JL, Janowsky DS, Risch SC, et al. Physostigmine effects on serotonin uptake in human blood platelets. *Eur J Pharmacol*. 1985;109:91–96.
21. Tobe T, Izumikawa F, Sano M, et al. Release mechanisms of 5-HT in mammalian gastrointestinal tract – especially vagal release of 5-HT. In: Fujita T, editor *Endocrine gut-pancreas*. Amsterdam: Elsevier, 1976. p. 371–390.
22. Morrison SF, Callaway J, Milner TA, et al. Rostral ventrolateral medulla: a source of the glutamatergic innervation of the sympathetic intermediolateral nucleus. *Brain Res*. 1991;562(1):126–135.
23. Dupont LJ, Pype JL, Demedts MG, et al. The effects of 5-HT on cholinergic contraction in human airways in vitro. *Eur Respir J*. 1999;14(3):642–649.
24. Mills EH, Minson JB, Pilowsky PM, et al. N-methyl-D-aspartate receptors in the spinal cord mediate pressor responses to stimulation of the rostral ventrolateral medulla in the rat. *Clin Exp Pharmacol Physiol*. 1988;15(2):147–155.
25. Hand GA, Potts JT, Treuhart BS, et al. Static muscle contraction elicits a baroreflex-dependent increase in glutamate concentration in the ventrolateral medulla. *Brain Res*. 1997;748(1–2):211–218.
26. Ross CA, Ruggiero DA, Joh TH, et al. Rostral ventrolateral medulla: selective projections to the thoracic autonomic cell column from the region containing C₁ adrenaline neurons. *J Comp Neurol*. 1984;10;228(2):168–185.

27. Maling TJ, Dollery CT, Hamilton CA. Clonidine and sympathetic activity during sleep. *Clin Sci (Lond)*. 1979;57(6):509–514.
28. Lechin F, van der Dijs B, Pardey-Maldonado B, et al. Circulating neurotransmitter profiles during the different wake-sleep stages in normal subjects. *Psychoneuroendocrinology*. 2004;29:669–685.
29. Lechin F, van der Dijs B, Lechin ME. Neurocircuitry and neuroautonomic disorders: reviews and therapeutic strategies. Chapter 1. Basel: Karger, 2002:3–13.
30. Lechin F, van der Dijs B, Lechin E. The autonomic nervous system: Physiological basis of psychosomatic therapy. Chapter IV. Barcelona, Spain: Editorial Cientifico-Medica, 1979:41–64.
31. Lechin F, van der Dijs B. Neochemistry and clinical disorders: Circuitry of some psychiatric and psychosomatic syndromes. Chapter 1. Boca Raton, FL: CRC Press, 1989:1–48.
32. Kawahara Y, Kawahara H, Westerink BH. Tonic regulation of the activity of noradrenergic neurons in the locus coeruleus of the conscious rat studied by dual-probe microdialysis. *Brain Res*. 1999;823(1–2):42–48.
33. Reis DJ. Neurotransmitters acting in the C₁ area in the tonic and reflex control of blood pressure. Review. *J Cardiovasc Pharmacol*. 1987;10 Suppl 12:S22–S25.
34. Haselton JR, Guyenet PG. Electrophysiological characterization of putative C₁ adrenergic neurons in the rat. *Neuroscience*. 1989;30(1):199–214.
35. Ward DG, Gunn CG. Locus coeruleus complex: differential modulation of depressor mechanisms. *Brain Res*. 1976;107(2):407–411.
36. Huangfu D, Guyenet PG. Autoactivity of A5 neurons: role of sub-threshold oscillations and persistent Na⁺ current. *Am J Physiol*. 1997; 273(5 Pt 2):H2280–H2289.
37. Elam M, Thoren P, Svensson TH. Locus coeruleus and sympathetic nerves: activation by visceral afferents. *Brain Res*. 1986;375:117–125.
38. Wilson CG, Bonham AC. Area postrema excites and inhibits sympathetic-related neurons in rostral ventrolateral medulla in rabbit. *Am J Physiol*. 1994;266(3 Pt 2):H1075–H1086.
39. Urbanski RW, Sapru HN. Evidence for a sympathoexcitatory pathway from the nucleus tractus solitarii to the ventrolateral medullary pressor area. *J Auton Nerv Syst*. 1988;23(2):161–174.
40. Murase S, Takayama M, Nosaka S. Chemical stimulation of the nucleus locus coeruleus: cardiovascular responses and baroreflex modification. *Neurosci Lett*. 1993;153(1):1–4.
41. Ohliger-Frerking P, Horowitz JM, Horwitz BA. Enhanced adrenergic excitation of serotonergic dorsal raphe neurons in genetically obese rats. *Neurosci Lett*. 2002;332:107–110.
42. Egan TM, North RA. Acetylcholine acts on m2-muscarinic receptors to excite rat locus coeruleus neurones. *Br J Pharmacol*. 1985;85(4):733–735.
43. Woolf NJ, Butcher LL. Cholinergic systems in the rat brain: IV. Descending projections of the pontomesencephalic tegmentum. *Brain Res Bull*. 1989;23(6):519–540.
44. Li YW, Guyenet PG. Activation of GABAB receptors increases a potassium conductance in rat bulbospinal neurons of the C₁ area. *Am J Physiol*. 1996;271(5 Pt 2):R1304–R1310.
45. Huangfu D, Schreihofer M, Guyenet PG. Effect of cholinergic agonists on bulbospinal C₁ neurons in rats. *Am J Physiol*. 1997;272(1 Pt 2):R249–R258.
46. Van Gaalen M, Kawahara H, Kawahara Y, et al. The locus coeruleus noradrenergic system in the rat brain studied by dual-probe microdialysis. *Brain Res*. 1997;763(1):56–62.
47. Tao R, Auerbach SB. Influence of inhibitory and excitatory inputs on serotonin efflux differs in the dorsal and median raphe nuclei. *Brain Res*. 2003;961:109–120.
48. Pudovkina OL, Cremers TI, Westerink BH. The interaction between the locus coeruleus and dorsal raphe nucleus studied with dual-probe microdialysis. *Eur J Pharmacol*. 2002;445:37–42.
49. Lechin F, van der Dijs B. Central nervous system (CNS) circuitry involved in the hyperinsulinism syndrome. *Neuroendocrinology*. 2006;84:222–234.

Journal of Experimental Pharmacology

Publish your work in this journal

The Journal of Experimental Pharmacology is an international, peer-reviewed, open access journal publishing original research, reports, reviews and commentaries on all areas of laboratory and experimental pharmacology. The manuscript management system is completely online and includes a very quick and fair peer-review system.

Submit your manuscript here: <http://www.dovepress.com/journal-of-experimental-pharmacology-journal>

Dovepress

Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.